Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
about
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation.Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.Individualization of antiretroviral therapy.Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.Clinical pharmacokinetics of antiretroviral drugs in older persons.Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteersFactors influencing lopinavir and atazanavir plasma concentration.Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Pharmacogenetics of antiretroviral therapy.Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model.Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.
P2860
Q28546430-819A8134-CE64-457E-A4FC-BB36C7132FEBQ33787957-A943E646-D0DA-4F24-BEF4-6FE86ED69E62Q34309475-6BCB4B01-D1ED-416E-8B78-8F3C5A95907CQ35079510-67B5A0C2-618E-45CB-BDE4-4A7FA32EE1B8Q35629777-F6DEA159-33EF-4893-A5A5-970C410C0142Q36441423-38F80705-00E0-47C4-BCD2-F1E780E238F0Q36505387-D15A5D02-1134-49F6-8762-350ACD388317Q36675895-32B002F9-E5F0-4637-A5D4-C8B223F912FCQ36905884-7EDF192F-4564-4F6D-96F2-09F68C843813Q37187471-C2FB5CD8-64B2-401F-9FC0-AC03877B631FQ37476403-9360C633-DFB2-45E7-A443-ADE33639D7E5Q37611687-1C0EF07B-4783-43FB-A391-D77B7D967A2BQ37866298-7459A888-6473-4D83-B76D-613BAE5D13C2Q38221179-81249DCD-ADB1-4AD8-8F1B-597F366B0996Q40603398-ED9736FA-CB6D-4243-BEAB-319B2C879A85Q42263920-615015D4-7FC9-4040-AF24-342CE01FD673Q43654216-C2522436-D1B5-417C-93B3-7D05EDB06770Q43699242-410221A0-B370-4698-ACAF-9361B0E39DD3
P2860
Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Population pharmacokinetics of ...... iency virus-infected patients.
@en
Population pharmacokinetics of ...... iency virus-infected patients.
@nl
type
label
Population pharmacokinetics of ...... iency virus-infected patients.
@en
Population pharmacokinetics of ...... iency virus-infected patients.
@nl
prefLabel
Population pharmacokinetics of ...... iency virus-infected patients.
@en
Population pharmacokinetics of ...... iency virus-infected patients.
@nl
P2093
P1476
Population pharmacokinetics of ...... iency virus-infected patients.
@en
P2093
Alain Lafeuillade
Bruno Lacarelle
Caroline Solas
Isabelle Ravaux
Marie-Claude Gagnieu
Marie-Pierre Drogoul
Nicolas Simon
Saadia Mokhtari
P304
P356
10.1097/FTD.0B013E3181897BFF
P577
2008-12-01T00:00:00Z